Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Adverum Biotechnologies, Inc. (NASDAQ: ADVM).

Full DD Report for ADVM

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADVM)

Adverum Biotechnologies Presents Additional Long-term Preclinical Data on ADVM-022 in Wet AMD at ASGCT 21st Annual Meeting
-- Single Intravitreal Administration of Gene Therapy ADVM-022 Provides Long-term Protection in Nonhuman Primate Model of Wet AMD -- MENLO PARK, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet...
Source: GlobeNewswire
Date: May, 17 2018 20:15
After Hours Gainers / Losers (05/11/2018)
Top gainers:   NEWT   +3.8% .  ANFI +2.8% . VSLR   +2.3% . SNCR +2.1% . ZTO   +2.0% . More news on: Newtek Business Services Inc., Amira Nature Foods, Vivint Solar, Stocks on the move, , News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 11 2018 17:39
Adverum Biotechnologies misses by $0.01, misses on revenue
Adverum Biotechnologies (NASDAQ: ADVM ): Q1 EPS of -$0.30 misses by $0.01 . More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 09 2018 16:40
Adverum Biotechnologies Reports First Quarter 2018 Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today reported financial results for the first quarter ended March 31, 2018 and provided...
Source: GlobeNewswire
Date: May, 09 2018 16:00
Midday Gainers / Losers (05/04/2018)
Gainers:   BSPM +33% . CVGI +35% . CRC +27% . EARS +26% . P +23% . KONA +23% . NGVC +22% . MED +22% . SHAK +22% . PTLA +21% . More news on: Biostar Pharmaceutic, Commercial Vehicle Group, Inc., California Resources Corporation, Stocks on the move, , ...
Source: SeekingAlpha
Date: May, 04 2018 13:15
Adverum -9.5% amid departures of CEO, chief medical officer
Adverum Biotechnologies (NASDAQ: ADVM ) is 9.5% lower after hours following word that CEO/President Amber Salzman is stepping down from those roles and the board. More news on: Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 03 2018 18:26
Adverum Biotechnologies Announces Leadership Changes
MENLO PARK, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced that the board of directors and Amber Salzman, Ph.D., president and chief exec...
Source: GlobeNewswire
Date: May, 03 2018 16:30
Adverum Biotechnologies Announces Long-term Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD
-- 13-Month Data Show Efficacy and Durability of Protein Expression following a  Single Intravitreal Administration of ADVM-022 -- -- Data to be Presented in a Poster Session on May 17, 2018 at the ASGCT 21 st Annual Conference -- MENLO PARK, Calif., May 01, 2018 (GLOBE NEW...
Source: GlobeNewswire
Date: May, 01 2018 09:00
Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Teck Resources Ltd (NYSE:TECK), Adverum Biotechnologies, Inc. (NASDAQ:AD...
Source: GlobeNewswire
Date: April, 09 2018 07:40
Novartis takeout of AveXis stokes buying in gene therapy players
Gene therapy developers bluebird bio (NASDAQ: BLUE ) and Audentes Therapeutics (NASDAQ: BOLD ) are up  8%  and  10%  premarket, respectively, both on light volume on the heels of Novartis' $8.7B bid for AveXis. More news on: bluebird bio, Inc., Audentes Therapeutics, In...
Source: SeekingAlpha
Date: April, 09 2018 07:19

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-246.106.1756.206.05175,793
2018-05-235.956.1756.205.95225,179
2018-05-225.806.006.1255.75634,492
2018-05-186.106.1256.355.975852,931
2018-05-176.206.006.205.70690,550

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2410,97529,66736.9940Short
2018-05-2327,05788,34930.6251Cover
2018-05-2222,873239,8769.5353Cover
2018-05-2142,614218,37819.5139Cover
2018-05-18103,398296,46734.8767Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADVM.


About Adverum Biotechnologies, Inc. (NASDAQ: ADVM)

Logo for Adverum Biotechnologies, Inc. (NASDAQ: ADVM)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ADVM)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 20 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 20 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 16 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 23 2018
      Amendment to a previously filed 8-K
      Filing Type: 8-K/AFiling Source: edgar
      Filing Date: March, 22 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 06 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 22 2018

       

       


      Daily Technical Chart for (NASDAQ: ADVM)

      Daily Technical Chart for (NASDAQ: ADVM)


      Stay tuned for daily updates and more on (NASDAQ: ADVM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ADVM)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      OTC Report
      @OTCReporter

       

       


      Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADVM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ADVM and does not buy, sell, or trade any shares of ADVM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/